Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Multiple sclerosis
ADR ID BADD_A02874
ADR Hierarchy
10      Immune system disorders
10.04      Autoimmune disorders
10.04.10      Nervous system autoimmune disorders
10.04.10.008      Multiple sclerosis
17      Nervous system disorders
17.16      Demyelinating disorders
17.16.01      Multiple sclerosis acute and progressive
17.16.01.001      Multiple sclerosis
Description An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) [MeSH]
MedDRA Code 10028245
MeSH ID D009103
ADR Severity Grade (FAERS) Not Available
ADR Severity Grade (CTCAE) Not Available
Synonym
Disseminated sclerosis | MS | MS aggravated | MS-like syndrome | Multiple sclerosis | Multiple sclerosis aggravated | Multiple sclerosis like syndrome | Multiple sclerosis-like syndrome | Sclerosis multiple | Syndrome MS-like | Progression of multiple sclerosis | Multiple sclerosis plaque | Multiple sclerosis brain lesion | Multiple sclerosis spinal cord lesion | Multiple sclerosis lesion | Multiple Sclerosis | Sclerosis, Multiple | Sclerosis, Disseminated | Disseminated Sclerosis | MS (Multiple Sclerosis) | Multiple Sclerosis, Acute Fulminating
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01217Itraconazole0.002672%
BADD_D01243Lamotrigine--
BADD_D01285Levothyroxine--
BADD_D01304Lithium cation0.000192%
BADD_D01318Lorazepam--
BADD_D01366Medroxyprogesterone acetate0.000119%
BADD_D01433Methylprednisolone0.000080%
BADD_D01445Metoprolol--
BADD_D01475Mirabegron--
BADD_D01476Mirtazapine0.000160%
BADD_D01484Modafinil--
BADD_D01507Mycophenolate mofetil--
BADD_D01588Nortriptyline--
BADD_D01679Paroxetine--
BADD_D01741Perindoprilat--
BADD_D01775Pinaverium bromide--
BADD_D01835Pregabalin--
BADD_D01909Ramipril--
BADD_D01915Ranolazine0.000284%
BADD_D02095Sulfur colloid--
BADD_D02165Teriflunomide0.063798%
BADD_D02230Tizanidine0.000052%
BADD_D02244Tolterodine0.000339%
BADD_D02329Valproic acid0.000998%
BADD_D02332Vancomycin--
BADD_D02337Varenicline0.000487%
BADD_D02338Varenicline tartrate--
BADD_D02346Venlafaxine0.000048%
BADD_D02375Water--
BADD_D02393Zolmitriptan--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages